Overcoming the stromal barrier: technologies to optimize drug delivery in pancreatic cancer

Pancreatic cancer has historically proven resistant to anticancer agents. On the one hand, drugs might be more efficient if higher levels could be achieved at the tumor site rather than the normal tissues. On the other hand, the thick stroma and the relative absence of abundant vessels may account a...

Full description

Saved in:

Bibliographic Details
Published in:	Therapeutic Advances in Medical Oncology Vol. 4; no. 5; pp. 271 - 279
Main Authors:	Dimou, Anastasios, Syrigos, Konstantinos N., Saif, Muhammad Wasif
Format:	Book Review Journal Article
Language:	English
Published:	London, England SAGE Publications 01-09-2012 Sage Publications Ltd SAGE Publishing
Subjects:	Antitumor agents Clinical trials Drug delivery Malignancy Pancreatic cancer Reviews Stroma pancreatic cancer gemcitabine drug delivery folfirinox chemotherapy resistance
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Pancreatic cancer has historically proven resistant to anticancer agents. On the one hand, drugs might be more efficient if higher levels could be achieved at the tumor site rather than the normal tissues. On the other hand, the thick stroma and the relative absence of abundant vessels may account at least partially for the failure of successive clinical trials to demonstrate effective treatments in this type of malignancy. In this context, the development and testing in clinical trials of treatment strategies that aim to optimize drug delivery is an important target in improving the prognosis of patients with pancreatic cancer.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	1758-8340 1758-8359 1758-8359
DOI:	10.1177/1758834012446008